Key result
Obesity did not significantly alter 90-day venous thromboembolism incidence compared to normal weight in hospitalized patients receiving enoxaparin prophylaxis (OR 0.797; 95% CI 0.353-1.796).
Why the study?
Does standard prophylactic enoxaparin dosing provide similar prevention of venous thromboembolism in obese compared to non-obese hospitalized patients?
Population
428 hospitalized patients receiving prophylactic enoxaparin, stratified by BMI into non-obese, overweight…
Comparison
Standard FDA-approved prophylactic enoxaparin… vs Standard FDA-approved prophylactic enoxaparin…
Design
Cohort
Follow-up
90 days
Authors
Loading...
Supports standard enoxaparin dosing in obese patients; hypothesis-generating and requires prospective confirmation.
Cohort (n=428)
Yes
Does standard prophylactic enoxaparin dosing provide similar prevention of venous thromboembolism in obese compared to non-obese hospitalized patients?
Odds Ratio: 0.797 (95% CI 0.353–1.796)
p-value: p=0.81
Standard FDA-approved prophylactic doses of enoxaparin appear to provide similar VTE protection in obese and non-obese hospitalized patients.
Alnatsheh et al. (2018) conducted a cohort in Venous thromboembolism (n=428). Obesity (BMI ≥ 30 kg/m2) vs. Normal body weight (BMI < 25 kg/m2) was evaluated on Venous thromboembolism occurrence within 90 days (OR 0.797, 95% CI 0.353-1.796, p=0.81). Obesity did not significantly alter 90-day venous thromboembolism incidence compared to normal weight in hospitalized patients receiving enoxaparin prophylaxis (OR 0.797; 95% CI 0.353-1.796).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: